A Milestone Moment For Pharmacogenomics: US FDA Ready To Drop ‘Voluntary’ Program
Executive Summary
The US FDA’s plan to update a 20-year-old guidance on pharmacogenomic data submissions is a good time to reflect on the dramatic transformation of industry attitudes and approaches to targeted medicine over the past two decades.